Key facts
- It has raised $600K across 1 recorded rounds; the latest was Early Stage VC in Oct 2025.
- Notable investors include Y Combinator, Andreessen Horowitz, Pioneer Fund, Metaplanet Holdings, University of California — 18 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Kopra Bio
Funding rounds
1 roundsAbout Kopra Bio
Operator of a biological therapy platform intended for medical treatment. The company's platform uses engineered biological agents capable of selectively targeting diseased cells, reprogramming them to produce immune-stimulating factors and engage the body's own defenses, with features including selective delivery mechanisms, modulation of immune responses, integration with existing therapeutic strategies, and adaptability to research and clinical development, enabling the oncology and biomedical research market to explore approaches to treating aggressive diseases and potentially improve long-term therapeutic outcomes and patient responses.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 10
- Website
- kopra.bio/
- Ownership
- Privately Held (backing)
Kopra Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kopra Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kopra Bio in its N-PORT filings yet. We sweep new filings monthly.